Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Phase II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02244463
Recruitment Status : Recruiting
First Posted : September 19, 2014
Last Update Posted : May 27, 2020
Sponsor:
Collaborator:
Millennium Pharmaceuticals, Inc.
Information provided by (Responsible Party):
Jochen Lorch, MD, Dana-Farber Cancer Institute

Brief Summary:

This research study is studying a targeted therapy (ML0N128) as a possible treatment for anaplastic thyroid cancer.

This research study is a Phase II clinical trial. Phase II clinical trials test the safety and effectiveness of an investigational intervention to learn whether the intervention works in treating a specific disease. "Investigational" means that the intervention is being studied. The FDA (the U.S. Food and Drug Administration) has not approved MLN0128 as a treatment for any disease.

MLN0128 prevents tumor cells from dividing and growing by selectively and potently inhibiting a chemical, mTOR kinase, which regulates cell growth and survival. Patients with anaplastic thyroid cancer have been observed to sometimes carry genetic alterations in their tumor cells which may make the cancer more sensitive to inhibition by MLN0128.

In this research study,the investigators are investigating usefulness of MLN0128 in metastatic anaplastic thyroid cancer cases.


Condition or disease Intervention/treatment Phase
Anaplastic Thyroid Cancer Thyroid Cancer Drug: MLN0128 Phase 2

Detailed Description:

Patients who fulfill eligibility criteria will be entered into the trial to receive ML0N128. The participant will be given a study drug-dosing diary for each treatment cycle. After the screening procedures confirm participation in the research study.

- MLN0128 - Fixed doses daily per treatment cycle

The treatment cycles will continue until the participants disease gets worse or is taken off treatment for any other reason.Once treatment has been discontinued the investigators will check on the participants health status by phone for the rest of their life.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 25 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer
Actual Study Start Date : July 2015
Estimated Primary Completion Date : December 2020
Estimated Study Completion Date : January 2022

Resource links provided by the National Library of Medicine

Drug Information available for: Thyroid

Arm Intervention/treatment
Experimental: MLN0128
Treatment will be administered on an outpatient basis. MLN0128 at fixed dose will be administered orally, daily for treatment cycle. The participant will be requested to maintain a medication diary of medication. The medication diary will be returned to clinic staff at the end of each cycle. Treatment with MLN0128 will continue until progression or withdrawal of consent.
Drug: MLN0128
This is a non-randomized phase II study to investigate efficacy of MLN0128 in metastatic anaplastic thyroid cancer cases.
Other Name: INK128




Primary Outcome Measures :
  1. Progression Free Survival [ Time Frame: baseline, 4 months ]

Secondary Outcome Measures :
  1. Overall All Response Rate [ Time Frame: 2 Years ]
  2. Overall Survival Rate [ Time Frame: 2 Years ]
  3. Number of Participants with Serious and Non-Serious Adverse Events [ Time Frame: 2 Years ]
  4. • Identification of biomarkers predictive of response to therapy with MLN0128 [ Time Frame: 2 Years ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male or female patients 18 years or older
  • Any number of prior chemotherapy or targeted agents including rapamycin analogues allowed
  • Newly diagnosed or refractory/metastatic anaplastic thyroid cancer confirmed by histology, incurable by surgery, radiotherapy or chemoradiotherapy alone or in combination
  • Must have measurable disease
  • ECOG performance status 0-2
  • No active intracranial metastases
  • Tissue for correlative studies must be available
  • Ability to swallow oral medications
  • Voluntary written consent must be given before performance of any study related procedure
  • Adequate organ function, as specified below, within 21 days:

    • Bone marrow reserve consistent with: absolute neutrophil count (ANC) ≥ 1.5 x 109/L; platelet count ≥ 100 x 109/L; hemoglobin ≥ 9 g/dL;
    • Hepatic: total bilirubin ≤1.5 x upper limit of normal (ULN), transaminases (aspartate aminotransferase/serum glutamic oxaloacetic transaminase-AST/SGOT and alanine aminotransferase/serum glutamic pyruvic transaminase-ALT/SGPT) ≤2.5 x ULN (≤5 x ULN if liver metastases are present);
    • Renal: creatinine clearance ≥50 mL/min
    • Metabolic: fasting serum glucose (≤ 130 mg/dL) and fasting triglycerides ≤ 300 mg/dL
    • Left ventricular ejection fraction (LVEF) within 5 absolute percentage points of institutional standard of normal as measured by echocardiogram (ECHO) or multiple gated acquisition scan (MUGA) within 4 weeks prior to first study drug administration (ie, if the institutional normal is 50%, subject's LVEF may be as low as 45% to be eligible for the study)
  • Female patients who:

    • Are postmenopausal for at least 1 year before the screening visit, OR
    • Are surgically sterile, OR
    • If they are of childbearing potential, agree to practice 2 effective methods of contraception, at the same time, from the time of signing the informed consent through 90 days after the last dose of study drug, or agree to completely abstain from heterosexual intercourse
  • Male patients, even if surgically sterilized (ie, status post-vasectomy), who:

    • Agree to practice effective barrier contraception during the entire study treatment period and through 90 days after the last dose of study drug, or
    • Agree to completely abstain from heterosexual intercourse
  • Treatment with strong CYP2C19, CYP3A4, and CYP2C9 inhibitors and/or inducers must be discontinued

Exclusion Criteria:

  • Female patients who are both lactating and breastfeeding or have a positive serum pregnancy test during the screening period
  • Any serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with the completion of treatment
  • Treatment with any investigational products within 14 days
  • Failed to recover from the reversible effects of prior anticancer therapies
  • Manifestations of malabsorption due to prior gastrointestinal surgery or disease
  • Poorly controlled diabetes mellitus
  • History of any of the following within the last 6 months prior to study entry:

    • Ischemic myocardial event
    • Ischemic cerebrovascular event
    • Requirement for inotropic support (excluding digoxin) or serious (uncontrolled) cardiac arrhythmia
    • Placement of a pacemaker for control of rhythm
    • New York Heart Association Class III or IV heart failure
    • Pulmonary embolism
  • Significant active cardiovascular or pulmonary disease at the time of study entry, including:

    • Uncontrolled high blood pressure
    • Pulmonary hypertension
    • Uncontrolled asthma or O2 saturation < 90%
    • Significant valvular disease
    • Medically significant (symptomatic) bradycardia
    • History of arrhythmia requiring an implantable cardiac defibrillator
    • Baseline prolongation of the rate-corrected QT interval (QTc)
  • Treatment with hematopoietic growth factors, transfusions of blood and blood products, or systemic corticosteroids

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02244463


Contacts
Layout table for location contacts
Contact: Jochen Lorch, MD 617) 632-3090 JLORCH@partners.org

Locations
Layout table for location information
United States, California
Hoag Memorial Hospital Presbyterian Recruiting
Newport Beach, California, United States, 92663
Contact: Michael Demeure, MD    949-791-6767    Michael.Demeure@hoag.org   
United States, Massachusetts
Dana-Farber Cancer Institute Recruiting
Boston, Massachusetts, United States, 02115
Contact: Jochen Lorch, MD    617-632-3090    jlorch@partners.org   
Principal Investigator: Jochen Lorch, MD         
United States, Michigan
University of Michigan Medical School Recruiting
Ann Arbor, Michigan, United States, 48109
Contact: Francis Worden, MD    734-647-8902    fworden@med.umich.edu   
Sponsors and Collaborators
Dana-Farber Cancer Institute
Millennium Pharmaceuticals, Inc.
Investigators
Layout table for investigator information
Principal Investigator: Jochen Lorch, MD. PhD Dana-Farber Cancer Institute
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Jochen Lorch, MD, Principal Investigator, Dana-Farber Cancer Institute
ClinicalTrials.gov Identifier: NCT02244463    
Other Study ID Numbers: 14-223
First Posted: September 19, 2014    Key Record Dates
Last Update Posted: May 27, 2020
Last Verified: May 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: There are no plans to share individual participant data. Cumulative results will be posted here and published.
Keywords provided by Jochen Lorch, MD, Dana-Farber Cancer Institute:
Anaplastic Thyroid Cancer
Thyroid Cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Thyroid Neoplasms
Thyroid Carcinoma, Anaplastic
Thyroid Diseases
Endocrine System Diseases
Endocrine Gland Neoplasms
Neoplasms by Site
Neoplasms
Head and Neck Neoplasms
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type